Applied Therapeutics (APLT) Net Margin (2023 - 2025)
Historic Net Margin for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to 1661.4%.
- Applied Therapeutics' Net Margin rose 216058100.0% to 1661.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 9631.2%, marking a year-over-year decrease of 941162700.0%. This contributed to the annual value of 22146.15% for FY2024, which is 209476800.0% down from last year.
- Applied Therapeutics' Net Margin amounted to 1661.4% in Q3 2025, which was up 216058100.0% from 23267.21% recorded in Q3 2024.
- Applied Therapeutics' Net Margin's 5-year high stood at 5649.03% during Q4 2023, with a 5-year trough of 41969.0% in Q1 2024.
- Its 3-year average for Net Margin is 12517.0%, with a median of 7709.87% in 2024.
- In the last 5 years, Applied Therapeutics' Net Margin crashed by -418739100bps in 2024 and then surged by 216058100bps in 2025.
- Over the past 3 years, Applied Therapeutics' Net Margin (Quarter) stood at 5649.03% in 2023, then tumbled by -512bps to 23267.21% in 2024, then skyrocketed by 93bps to 1661.4% in 2025.
- Its Net Margin stands at 1661.4% for Q3 2025, versus 23267.21% for Q3 2024 and 13758.33% for Q2 2024.